PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.
Excess sodium intake may increase the risk of eczema flares
UCSF study finds that changes in daily salt intake may explain eczema flares.
UCSF study finds that changes in daily salt intake may explain eczema flares.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes